BioKangtai Celebrates a Significant Milestone Achievement

Date:2025.08.25

类型: 行业动态

分享:

图片名称
图片名称

We are proud to announce the successful commercialization of the world’s first “dual-vector PCV13 (TT/DT)” through our localization program in Indonesia. 

 

This achievement goes far beyond a product launch — it represents BioKangtai’s first end-to-end technology transfer program to reach market overseas. By enabling local fill-finish production, the vaccine received regulatory approval in Indonesia.

 

Key highlights:

· Protection against 13 serotypes

· Approved for the full age range: 6 weeks to 5 years

· Supports Indonesia’s national drive for vaccine self-reliance and equitable access

 

We sincerely thank our Indonesian partner for making this milestone possible. Looking ahead, we will continue to expand technology-transfer partnerships, helping strengthen global health systems and safeguarding communities worldwide.